- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/00 - Drugs for disorders of the metabolism
Patent holdings for IPC class A61P 3/00
Total number of patents in this class: 7006
10-year publication summary
258
|
242
|
392
|
467
|
471
|
564
|
511
|
525
|
492
|
201
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Mondobiotech Laboratories AG | 311 |
282 |
F. Hoffmann-La Roche AG | 7912 |
66 |
Bristol-myers Squibb Company | 4896 |
59 |
Boehringer Ingelheim International GmbH | 4702 |
56 |
Takeda Pharmaceutical Company Limited | 2703 |
56 |
Janssen Pharmaceutica N.V. | 3431 |
54 |
Novartis AG | 10963 |
47 |
Amicus Therapeutics, Inc. | 348 |
43 |
The Trustees of the University of Pennsylvania | 4295 |
40 |
Modernatx, Inc. | 1258 |
40 |
Société des Produits Nestlé S.A. | 9168 |
39 |
Regeneron Pharmaceuticals, Inc. | 4211 |
38 |
Pfizer Inc. | 3352 |
37 |
Eli Lilly and Company | 3797 |
37 |
sanofi-aventis | 377 |
33 |
Amgen Inc. | 4024 |
32 |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 818 |
32 |
University of Pittsburgh - Of the Commonwealth System of Higher Education | 3115 |
32 |
The Regents of the University of California | 19784 |
30 |
Genzyme Corporation | 1231 |
29 |
Other owners | 5924 |